Warning: The NCBI web site requires JavaScript to function. more...
Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M.
Arthritis Res Ther. 2006;8(4):R119.
Related citations
Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.
J Rheumatol. 2007 Aug;34(8):1658-63. Epub 2007 Jul 1.
Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, Sengül A.
Protein Pept Lett. 2008;15(3):314-7.
Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
Arthritis Rheum. 2008 Jan;58(1):36-45.
Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays.
Vander Cruyssen B, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F.
Arthritis Res Ther. 2006;8(4):R122.
Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis.
Mutlu N, Bicakcigil M, Tasan DA, Kaya A, Yavuz S, Ozden AI.
J Rheumatol. 2009 Mar;36(3):491-500. Epub 2009 Feb 17.
The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X, Jia R, Zhao J, Li Z.
J Rheumatol. 2009 Jun;36(6):1136-42. Epub 2009 May 15.
Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?
Szekanecz Z, Soós L, Szabó Z, Fekete A, Kapitány A, Végvári A, Sipka S, Szücs G, Szántó S, Lakos G.
Clin Rev Allergy Immunol. 2008 Feb;34(1):26-31. Review.
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, Dieudé P, Meyer O, Chollet Martin S.
Arthritis Res Ther. 2008;10(6):R142. Epub 2008 Dec 10.
Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?
Vannini A, Cheung K, Fusconi M, Stammen-Vogelzangs J, Drenth JP, Dall'Aglio AC, Bianchi FB, Bakker-Jonges LE, van Venrooij WJ, Pruijn GJ, Zendman AJ.
Ann Rheum Dis. 2007 Apr;66(4):511-6. Epub 2006 Sep 19.
Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A, Plischke H, Kellner H, Gruber R.
Ann N Y Acad Sci. 2005 Jun;1050:295-303.
Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR.
Arthritis Rheum. 2007 Aug;56(8):2503-11.
Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis.
Wagner E, Skoumal M, Bayer PM, Klaushofer K.
Rheumatol Int. 2009 Sep;29(11):1315-21. Epub 2009 Jan 28.
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ.
Arthritis Rheum. 2000 Jan;43(1):155-63.
Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.
Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE, Huizinga TW, van der Helm-van Mil AH.
Ann Rheum Dis. 2010 Apr;69(4):730-2. Epub 2009 May 17.
Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios.
Pietrapertosa D, Tolusso B, Gremese E, Papalia MC, Bosello SL, Peluso G, Petricca L, Michelutti A, Faustini F, Fedele AL, Ferraccioli G.
Clin Chem Lab Med. 2010 Jun;48(6):829-34.
Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis.
Coenen D, Verschueren P, Westhovens R, Bossuyt X.
Clin Chem. 2007 Mar;53(3):498-504. Epub 2007 Jan 26.
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engström A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmström V.
Arthritis Rheum. 2010 Jan;62(1):44-52.
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, Uhlig T, Gaarder PI, Kvien TK.
Ann Rheum Dis. 2010 Feb;69(2):345-51. Epub 2009 Jul 30.
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
J Rheumatol. 2008 Jun;35(6):1002-8. Epub 2008 Apr 1.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on